Information Provided By: 
Fly News Breaks for April 7, 2016
AGN, PFE
Apr 7, 2016 | 07:46 EDT
JPMorgan analyst Chris Schott reinstated an Overweight rating on shares of Pfizer (PFE) following a period of restriction. The company's improving business fundamentals and attractive valuation should provide a floor for the shares following the failed merger with Allergan (AGN), Schott tells investors in a research note. The analyst says he wouldn't be surprised to see Pfizer pursue a break-up and/or additional mid-to-large sized business development transactions over the next 12-24 months. He has a $38 price target for the shares.
News For PFE;AGN From the Last 2 Days
PFE
Apr 25, 2024 | 10:25 EDT
Bullish option flow detected in Pfizer with 50,393 calls trading, 2x expected, and implied vol increasing over 2 points to 28.83%. Sep-24 27.5 calls and Mar-25 42.5 calls are the most active options, with total volume in those strikes near 27,600 contracts. The Put/Call Ratio is 0.21. Earnings are expected on May 1st.
